Original Article

Prevalence of Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Subclinical Infection in Patients with Acute Immune Thrombocytopenic Purpura (ITP)

Abstract

Background: Immune thrombocytopenic purpura (ITP) is defined as a bleeding disorder in which the number and production of platelets are reduced by the immune system; however, the destruction of peripheral blood platelets also occurs. Although its exact etiology and pathogenesis have not already known, several studies have shown that Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are known as possible causative agents of ITP. This investigation aims to evaluate the presence of CMV and EBV in two groups of case and control by polymerase chain reaction (PCR).

Materials and Methods: we considered the presence of CMV and EBV in 48 acute ITP patients and 48 healthy people. Study participants were recruited from Ahvaz Shafa Hospital between 2017 and 2018 and the presence of two viruses was investigated by (PCR).

Results: Out of 48 acute ITP patients, the CMV DNA was detected from the blood of 12 (25%) patients and the EBV DNA from the blood of 2 (4.2%) other patients. Also, only one patient was (2.1%) co-infected with CMV and EBV. In contrast, in 48 healthy subjects, 3 (6.6%) had CMV and none of the control group was infected with EBV.

Conclusion: Due to the presence of both EBV and CMV in the acute ITP patients in Ahvaz, they can be considered as factors in the progression of this disease. Therefore, consideration of the methods of elimination and treatment of these two viruses in these patients may be used as a treatment strategy in ITP patients in the future.

1. Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). Journal of clinical medicine. 2017;6(2):16.
2. McMillan R, editor Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Seminars in hematology; 2000: Elsevier.
3. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-93.
4. Swinkels M, Rijkers M, Voorberg J, Vidarsson G, Leebeek FW, Jansen A. Emerging concepts in immune thrombocytopenia. Frontiers in immunology. 2018;9:880.
5. Nomura S. Advances in diagnosis and treatments for immune thrombocytopenia. Clinical Medicine Insights: Blood Disorders. 2016;9:CMBD. S39643.
6. Vaillant AAJ, Gupta N. Thrombocytopenic Purpura Immune. 2019.
7. Behzad MM, Asnafi AA, Jaseb K, Jalali Far MA, Saki N. Expression of CD markers' in immune thrombocytopenic purpura: prognostic approaches. Apmis. 2017;125(12):1042-55.
8. Rodeghiero F, Besalduch J, Michel M, Provan D, Grotzinger K, Thompson G. Treatment practices in adults with chronic immune thrombocytopenia–a European perspective. European journal of haematology. 2010;84(2):160-8.
9. Zhu F, Qiao J, Cao J, Sun H-y, Wu Q-y, Sun Z-t, et al. Decreased level of cytotoxic T lymphocyte antigen-4 (CTLA-4) in patients with acute immune thrombocytopenia (ITP). Thrombosis research. 2015;136(4):797-802.
10. Smalisz-Skrzypczyk K, Romiszewski M, Matysiak M, Demkow U, Pawelec K. The influence of primary cytomegalovirus or Epstein-Barr virus infection on the course of idiopathic thrombocytopenic purpura. Advances in Clinical Science: Springer; 2015. p. 83-8.
11. Rezaeeyan H, Jaseb K, Alghasi A, Asnafi AA, Saki N. Association between gene polymorphisms and clinical features in idiopathic thrombocytopenic purpura patients. Blood Coagulation & Fibrinolysis. 2017;28(8):617-22.
12. Wei S-H, Ho M-C, Ni Y-H, Lin D-T, Lee P-H. Cytomegalovirus-associated immune thrombocytopenic purpura after liver transplantation. Journal of the Formosan Medical Association. 2007;106(4):327-9.
13. Wu Z, Zhou J, Wei X, Wang X, Li Y, Peng B, et al. The role of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) in immune thrombocytopenia. Hematology. 2013;18(5):295-9.
14. Medović R, Igrutinović Z, Radojević-Marjanović R, Marković S, Rašković Z, Simović A, et al. Clinical and laboratory differences between Epstein-Barr and cytomegalovirus infectious mononucleosis in children. Srp Arh Celok Lek. 2016;144(1-2):56-62.
15. Barsam SJ, Psaila B, Forestier M, Page LK, Sloane PA, Geyer JT, et al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood. 2011;117(21):5723-32.
16. Sheng Yu Z, Tang LF, Zou CC, Yan Zheng J, Zhao ZY. Cytomegalovirus-associated idiopathic thrombocytopenic purpura in Chinese children. Scandinavian journal of infectious diseases. 2008;40(11-12):922-7.
17. Jin MJ, Kim Y, Choi EM, Shim YJ, Kim HS, Suh JK, et al. Clinical characteristics and treatment courses for cytomegalovirus-associated thrombocytopenia in immunocompetent children after neonatal period. Blood research. 2018;53(2):110-6.
18. Flores-Chang BS, Arias-Morales CE, Wadskier FG, Gupta S, Stoicea N. Immune thrombocytopenic purpura secondary to cytomegalovirus infection: a case report. Frontiers in Medicine. 2015;2:79.
19. Hsiao CC. Epstein–Barr virus associated with immune thrombocytopenic purpura in childhood: A retrospective study. Journal of paediatrics and child health. 2000;36(5):445-8.
20. Zaki MES, Morcous H. Parvovirus B19, rubella, Epstein–Barr, and cytomegalovirus and idiopathic thrombocytopenia in Egyptian children, single-center study. The Egyptian Journal of Haematology. 2012;37(3):178.
21. Ahmed A. Immunopathology of CMV Co-infection: review. MOJ Immunol. 2014;1(3):00017.
22. Bravender T. Epstein-Barr virus, cytomegalovirus, and infectious mononucleosis. Adolescent medicine: state of the art reviews. 2010;21(2):251-64, ix.
23. DiMaggio D, Anderson A, Bussel JB. Cytomegalovirus can make immune thrombocytopenic purpura refractory. British journal of haematology. 2009;146(1):104-12.
24. Tanaka M, Kamijo T, Nakazawa Y, Kurokawa Y, Sakashita K, Komiyama A, et al. Specific Autoantibodies to Platelet Glycoproteins in Epstein-Barr Virus—Associated Immune Thrombocytopenia. International journal of hematology. 2003;78(2):168-70.
Files
IssueVol 15 No 3 (2021) QRcode
SectionOriginal Article(s)
Published2021-07-14
DOI https://doi.org/10.18502/ijhoscr.v15i3.6843
Keywords
Immune thrombocytopenic purpura (ITP); Cytomegalovirus (CMV); Epstein-barr virus (EBV)

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Abbasi F, Kaydani GA, Tahannejad Z, Nakhaie M, Aminasnafi A, Moradi M. Prevalence of Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Subclinical Infection in Patients with Acute Immune Thrombocytopenic Purpura (ITP). Int J Hematol Oncol Stem Cell Res. 2021;15(3):139-144.